Novartis presented compelling interim results from the Phase III ALIGN study evaluating the efficacy of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN). This data was highlighted at the European Renal Association (ERA) Congress, showcasing a significant 36.1% reduction in proteinuria at 36 weeks compared to placebo, […]
Swiss pharmaceutical giant Novartis has wrapped up the previously announced $3.5 billion acquisition of Seattle-based biopharmaceutical firm Chinook Therapeutics, Inc. This deal propels Novartis deeper into the realm of kidney disease treatments, capitalizing on Chinook Therapeutics’ cutting-edge precision medicines. Chinook Therapeutics’ promising pipeline, boasting two advanced assets, atrasentan and zigakibart (BION-1301), specifically targets Immunoglobulin A […]
Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington in a deal worth up to around $3.5 billion. The acquisition will bring two late-stage medicines for rare, severe chronic kidney diseases into Novartis’ portfolio. It aligns with Novartis’ strategy to focus on innovative medicines and will […]
Chinook Therapeutics, a US-based biopharma company, has secured orphan drug designation for atrasentan from the European Commission (EC) for the treatment of primary IgA nephropathy (IgAN). The decision from the EC comes after the adoption of a positive opinion by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). Atrasentan has […]
